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antimicrobial-susceptible and -resistant pathogens were obtained
from the literature or estimated. Resistance and co-resistance
prevalence to ﬁrst- and second-line therapy for the major CAP
pathogens were also derived from local surveillance studies.
Resource use was obtained from Canadian published sources.
Total costs were estimated using standard Ontario sources and a
third-party payer perspective. Outcome measures included ﬁrst-
line clinical failure, second-line treatment and hospitalizations
avoided. RESULTS: The base case incremental cost-effectiveness
ratios (ICERs) comparing moxiﬂoxacin/azithromycin with
azithromycin/moxiﬂoxacin were CDN$96.04 per clinical failure
avoided, CDN$118.71 per second-line treatment avoided, and
CDN$502.47 per hospitalization avoided. One-way sensitivity
analyses demonstrated that the model is robust to change.
The probabilistic sensitivity analysis reported a mean ICER of
CDN$133 (Sd601.47) per clinical failure avoided and a 22%
probability of a moxiﬂoxacin/azithromycin strategy being
cost-saving compared to azithromycin/moxiﬂoxacin. CONCLU-
SION: Antimicrobial failure signiﬁcantly affected outcomes and
costs in empirical outpatient CAP treatment. Despite the higher
costs of proprietary antimicrobial treatments in Canada com-
pared to generic treatments, ﬁrst-line treatment with a ﬂuoroqui-
nolone effective against the major CAP pathogens, including
strains resistant to other antimicrobials, produces signiﬁcantly
better clinical outcomes and relatively low total treatment costs
compared to generic drugs.
PRS10
ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB
USE FORTREATING ASTHMA IN A MANAGED CARE
POPULATION
Prescott J
The MCM Group, Marlton, NJ, USA
OBJECTIVE: The objectives of this analysis were to: 1)Identify a
population of asthma patients new to treatment with omali-
zumab; 2)measure asthma-speciﬁc treatment costs and utilization
for patients initiating treatment with omalizumab; and compare
and quantify, on an annual basis, differences in economics and
other measurable outcomes following initiation of treatment
with omalizumab. METHODS: Using integrated medical and
pharmacy claims data (obtained from the IMS/Pharmetrics
Patient-centric Database), patients were included in the analysis
based on the presence of a diagnosis of asthma (ICD-9 code
493.*) during calendar years 2004 through 2005. Additional
requirements included incident (new) use of omalizumab in
2004. Clinical and economic information related to the treat-
ment of asthma were captured using Episode Treatment Group
(ETG) episode-building software. RESULTS: In 2004, 542
patients (representing 0.1% of the overall asthma population)
were identiﬁed as being newly treated with omalizumab. Within
this group, 66% were diagnosed with extrinsic asthma and 78%
with rhinitis. Total annual costs related to the care of asthma for
this group was $16,643 with $5,926 in medical expenditures.
Following these patients into the next calendar year (2005),
pharmacy costs increased by 33% but medical costs decreased by
42% (to $3411), driven primarily by lower inpatient utilization,
admission rates (from 6.1% to 3.8%), and emergency room
utilization. Additionally, there was decreased use of oral corti-
costeroids and overall use of asthma controllers. CONCLU-
SION: Treatment with omalizumab represents a signiﬁcant
pharmacy investment, and measurable beneﬁts were observed
with respect to medical expenditures and asthma-speciﬁc out-
comes. However, these observations are limited to a very speciﬁc
patient population and further study may be necessary to deter-
mine applicability to other patient groups.
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OBJECTIVE: To compare cost-effectiveness (CE) and cost-utility
(CU) for varenicline vs. other interventions used for smoking
cessation in Czech Republic. METHODS: The Beneﬁt of
Smoking Cessation on Outcomes (BENESCO) Markov simula-
tion model was employed to compare different approaches. The
model simulates morbidity and mortality for the Czech popula-
tion of smokers. In our model a 20-years time horizon was used
to calculate costs and beneﬁts from the payer’s perspective under
current conditions (smoking cessation interventions are not reim-
bursed). Five co-morbidities were considered: chronic obstructive
pulmonary disease, coronary heart disease, stroke, lung cancer
and asthma exacerbations. Calculations were performed in 2007
costs and prices, assuming that 25% of smokers in each age
group make one attempt to quit smoking. Abstinence rates were
extrapolated from literature sources. Local costs and data were
obtained either from literature or expert panels. Assessed inter-
ventions included varenicline, bupropion, nicotine replacement
therapy (NRT) and unaided cessation. RESULTS: Varenicline
dominated all other interventions both in QALY and LYG, and
was cost-saving over the assessed period of 20 years. Beneﬁt of
varenicline was most signiﬁcant in comparison with unaided
cessation (QALY gained 18,186, LYG 12,243, deaths avoided
2004, costs saved €35.5 million—data for all smokers exposed to
intervention). Varenicline was also dominant in comparison to
the most frequently used approach—NRT (QALY gained 7358,
LYG 4953, deaths avoided 811, costs saved €13 million). Bupro-
pion showed similar results to NRT. Varenicline dominated all
other interventions already after ﬁve years. CONCLUSION:
Varenicline is the most effective and cost-effective smoking ces-
sation intervention in Czech Republic from the health care
payer’s perspective. As the prevalence of smokers is high; health
care providers should consider smoking cessation support,
including reimbursement strategies. Further scenarios to conﬁrm
CE and CU also under these conditions are needed.
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OBJECTIVE: To assess the incremental cost-effectiveness of
combining tiotropium (TIO) with salmeterol (SAL) or
salmeterol-ﬂuticasone (SFC) in moderate to severe COPD com-
pared with TIO alone. METHODS: A Markov model was con-
structed to estimate the incremental quality-adjusted life-years
(QALYs) of the three treatment arms. Efﬁcacy data were
obtained from a recently published large randomized controlled
study (Canadian Optimal Therapy of COPD trial). Cost data
were obtained from publicly available data. The cycle length for
the model was set to 3 months and the maximum time horizon
was set to 3 years. The cost-effective analysis was conducted
from a third-party payer’s perspective in the US health care
system. Future costs and effects were discounted at 3%. All costs
are reported in 2007 dollars. Multiple one-way sensitivity analy-
ses and a Monte Carlo simulation were performed to handle
uncertainty. RESULTS: Incremental cost-effectiveness ratios
compared with TIO alone were $152,743/QALY in the
TIO + SAL group, and $51,610/QALY in the TIO + SFC group.
An acceptability curve revealed TIO + SAL was more cost-
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effective when a willingness to pay (WTP) was $33,000/QALY
or less and TIO + SFC was more cost-effective when a WTP
exceeded that threshold. The cost-effectiveness was also sensitive
to changes in several variables including the mortality rates and
utilities associated with TIO + SAL and TIO + SFC, as well as
the hospitalization rate associated with TIO + SAL. CONCLU-
SION: When monotherapy with TIO is not effective to control
moderate to severe COPD, adding SFC rather than SAL appears
to be a more reasonable approach from a cost-effectiveness
standpoint in the US health care system. However, the results
were sensitive to changes in several key variables.
PRS13
PEDIATRIC ASTHMA:AN EMPLOYER PERSPECTIVE ON
ANNUAL EMPLOYEE AND DEPENDENT COSTS FOR MEDICAL
CARE AND PRESCRIPTION DRUGS
Kleinman N1, Brook RA2, Ramachandran S3,Wagner S3
1The HCMS Group, Cheyenne,WY, USA, 2The JeSTARx Group,
Newfoundland, NJ, USA, 3AstraZeneca,Wilmington, DE, USA
OBJECTIVE: Management of pediatric asthma is known to be
very costly. However, little is known about the costs to the
parent. We aimed to objectively assess employee and dependent
costs for employees with children with asthma (EWCWA)
compared with employees with children without asthma
(EWCWOA). METHODS: A retrospective analysis was con-
ducted using multiple US-based employers’ data from 2001 to
2007. Data included medical claims, pharmacy claims, payroll,
work absence, and demographics. Asthma diagnosis (ICD-9
codes 493.xx) or pharmacy claims for an asthma controller
medication were used to identify employees with asthmatic
dependents aged <12 years for the EWCWA cohort. Employees
in the EWCWOA cohort were identiﬁed based on dependent age
and lack of an asthma diagnosis (ICD-9 code) or pharmacy claim
for a controller medication. The index date in the EWCWA
cohort was deﬁned as the date of ﬁrst asthma diagnosis during
2001 or later; the ﬁrst pediatric medical or pharmacy claim date
was used in the EWCWOA cohort. All costs were adjusted to
2007 dollars and incremental costs (EWCWA—EWCWOA)
were calculated using two-part regression models and presented
for health care and prescriptions. Regression models controlled
for demographics, job information, Charlson Co-morbidity
Index, and geographic region. RESULTS: Data were available for
the EWCWA (dependent age <4 yr: n = 4577; 4–7 yr: n = 4343;
8–11 yr: n = 3954; total <12 yr: n = 11,794) and EWCWOA
(dependent age <4 yr: n = 32,558; 4–7 yr: n = 28,017; 8–11 yr:
n = 27,863; total <12 yr: n = 64,812) cohorts. The incremental
annual costs (EWCWA—EWCWOA) for employees and depen-
dents (health care/prescriptions), respectively, were: dependent
age <4 years: -$56/$73† and $663†/$568†; 4–7 years: $199*/
$109† and $904†/$555†; 8–11 years: $364*/$116† and $1081†/
$586†; <12 years: $154†/$95 and $862/$534 (*P < 0.05,
†P < 0.01). CONCLUSION: Pediatric asthma results in signiﬁ-
cant additional costs for both employees and dependents.
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OBJECTIVE: The prevalence of chronic asthma has tripled
during last two decades in Finland, but overall costs of disease
management have not increased and patient level costs have
decreased signiﬁcantly. We analyzed with comprehensive time
series all expenditures as well as the effectiveness of interventions
such as the national action program (1994–2004) and develop-
ment of pharmacotherapy. METHODS: Finnish registry based
data from 1987 to 2005 was combined to evaluate all costs of
asthma. These included comprehensive health care costs, sick-
leave compensations, disability pensions, and loss of produc-
tivity; all converted to 2004 euros. Several scenarios were
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: The number of
patients with valid special reimbursement for asthma medication
increased signiﬁcantly (83,000 to 216,000) during the observa-
tion period yet the overall expenditure of care remained at the
level of 1987, at €240 million. Cost of medications doubled
during study period, but savings were achieved as other
expenditures, mainly hospitalizations, and loss of productivity
decreased by 50 to 75%. Treatment effectiveness increased as
asthma related deaths, disability pensions, sick-leave payments
and institutional care decreased signiﬁcantly (50 to 70%). The
cost-saving scenarios showed that a signiﬁcant part (40%) of
positive effects was attained by launch of new asthma drugs and
asthma pipes from 1989 to 1994. The initiation of the national
care programme with its focus on anti-inﬂammatory treatment
from disease onset, improved diagnostics and more active self
care further increased this positive trend. CONCLUSION: Com-
prehensive assessment of large patient cohorts and long term
economical outcomes is a useful method for evaluation of out-
comes in chronic diseases. Identiﬁcation of different cost drivers
is needed as the cost of new interventions is increasing and their
beneﬁts should ideally be assessed in relation to their broader
societal inﬂuence.
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OBJECTIVE: The prevalence and costs of allergic rhinitis (AR)
in the United States are estimated to be very high. Recently,
research has reported that not all AR symptoms are of equal
importance to patients. In particular, evidence is mounting that
nasal congestion is the most bothersome symptom of AR and
thus may account for most of the burden of illness. However,
unlike AR which has an ICD-9-CM code thus facilitating esti-
mates of burden of illness, the cost of nasal congestion must be
obtained indirectly. The purpose of the present analysis is to
estimate the national costs of AR that are attributable to nasal
congestion. METHODS: Data come from a recent national study
of the effect of AR symptoms on patients’ lives (e.g., sleep,
daytime somnolence, mood, and work and school productivity).
These relative effects of nasal congestion were then applied to
U.S. cost estimates derived from the literature and a national
employer claims database to estimate some of the economic
burden of AR that could be attributed to nasal congestion.
RESULTS: Results suggest that almost three-fourths of the cost
associated with burden of illness related to AR is attributable to
nasal congestion. Thus, approximately $3.4 billion of the $4.8
billion in direct costs for AR and approximately $3.1 billion of
the $4.3 billion in indirect costs for AR can be attributed to nasal
congestion. CONCLUSION: The direct and indirect costs attrib-
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